Paragon 28, Inc.: directors' dealings · United States · SEC (Form 4)

About Paragon 28, Inc.

Paragon 28, Inc. is a U.S.-based medical device company focused almost entirely on the foot and ankle orthopedic market. The company was listed on the NYSE under the ticker FNA and was headquartered in Englewood, Colorado, United States. Founded in 2010, Paragon 28 was built around a highly specialized strategy: concentrate product development, clinical education, and surgical instrumentation on a single, anatomically defined segment of orthopedics rather than competing as a broad-based implant manufacturer. Its business model centers on a comprehensive portfolio of foot and ankle solutions, including plates and plating systems, screws, staples, nails, fracture-fixation devices, forefoot products, ankle systems, solutions for progressive collapsing foot deformity (PCFD) and flatfoot, Charcot foot offerings, orthobiologics, and related surgical instrumentation. The company’s approach is procedure-driven, meaning its products are designed around the actual surgical workflows used by foot and ankle specialists. That positioning is intended to improve reproducibility, simplify procedures, and support better clinical outcomes. From a competitive standpoint, Paragon 28 occupied a niche but strategically attractive segment within orthopedics. It competed against much larger diversified medtech groups, yet its narrow focus gave it a differentiating edge in product depth, surgeon relationships, and innovation cadence. For investors, that specialization can be an advantage because it supports brand credibility and clinical expertise; at the same time, it requires continued commercial execution to expand penetration across hospitals and ambulatory settings. Recent company news highlighted continued product innovation. In 2024 and early 2025, Paragon 28 announced new launches and expanded offerings in trauma and fixation, reinforcing its position in complex foot and ankle care. A major corporate development came in January 2025, when Zimmer Biomet announced a definitive agreement to acquire Paragon 28, and the transaction was subsequently completed in April 2025. As a result, Paragon 28 became a wholly owned subsidiary of Zimmer Biomet, marking a significant strategic consolidation in the orthopedics sector. For market context, Paragon 28’s history as a public company on the NYSE in the United States is important: it reflects both the scale reached by the platform and the strategic value of its specialized portfolio. Before the acquisition closed, the company had also indicated a commercial footprint extending beyond the U.S., supporting international surgeon adoption and broader market access. Overall, Paragon 28 represents a focused orthopedics franchise built on foot-and-ankle expertise, product innovation, and a strong procedural offering.